American Journal of Ophthalmology
Volume 137, Issue 3 , Pages 453-458 , March 2004

Ciprofloxacin and levofloxacin resistance among methicillin-sensitive staphylococcus aureus isolates from keratitis and conjunctivitis

  • Fabiana B. Marangon, MD

      Affiliations

    • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • ,
  • Darlene Miller, MPH

      Affiliations

    • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • ,
  • Marcus S. Muallem, MD

      Affiliations

    • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • ,
  • Andre C. Romano, MD

      Affiliations

    • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • ,
  • Eduardo C. Alfonso, MD

      Affiliations

    • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • Corresponding Author InformationInquiries to Eduardo C. Alfonso MD, Bascom Palmer Eye Institute, 900 NW 17 St., Miami, Fl 33136, USA; fax: (305) 326–6337

,Accepted 6 October 2003.

References 

  1. Aswad MI, John T, Barza M, Kenyon K, Baum J. Bacterial adherence to extended wear soft contact lenses. Ophthalmology. 1990;97:296–302
  2. Gudmundsson OG, Ormerod LD, Kenyon KR, et al.  Factors influencing predilection and outcome of bacterial keratitis. Cornea. 1989;8:115–121
  3. Asbell P, Stenson LS. Ulcerative keratitis (survey of 30 years' laboratory experience). Arch Ophthalmol. 1982;100:77–80
  4. Ormerod LD, Hertzmark E, Gomez DS, et al.  Epidemiology of microbial keratitis in southern California. Ophthalmology. 1987;94:1322–1333
  5. Tuft SJ, Matheson M. In vitro antibiotic resistance in bacterial keratitis in London. Br J Ophthalmol. 2000;84:687–691
  6. Knauf HP, Sivany R, Southern PM, et al.  Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Cornea. 1996;15:66–71
  7. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497–1502
  8. Frohlich SJ, Mino de Kaspar H, Grasbon T, et al.  Bacterial keratitis. Microbiological analysis as a principle for therapeutic recommendations. Ophthalmologe. 1999;96:459–464
  9. Schaefer F, Bruttin O, Zografos L, et al.  Bacterial keratitis (a prospective clinical and microbiological study). Br J Ophthalmol. 2001;85:842–847
  10. Tazawa H, Ooishi M. MRSA ocular infections. Nippon Rinsho. 1992;50:1122–1126
  11. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci (detection methods and treatment of infections). Antimicrob Agents Chemother. 1989;33:995–999
  12. Barza M. Use of quinolones for treatment of ear and eye infections. Eur J Clin Microbiol Infect Dis. 1991;10:296–303
  13. Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol. 1991;112(4 Suppl):15S–24S
  14. Baum J, Barza M. The evolution of antibiotic therapy for bacterial conjunctivitis and keratitis (1970–2000). Cornea. 2000;19:659–672
  15. Blumberg HM, Rimland D, Carall DJ, et al.  Rapid development of ciprofloxacin resistance in methicillin-susceptible and resistant Staphylococcus aureus. J Infect Dis. 1991;163:1279–1285
  16. Maple P, Hamilton-Miller J, Brumfitt W. Ciprofloxacin resistance in methicillin and gentamicin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1989;8:622–624
  17. Shalit I, Berger SA, Gorea A, et al.  Widespread quinolone resistance among methicillin resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989;33:593–594
  18. Daum TE, Schaberg DR, Terpenning MS, et al.  Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob Agents Chemother. 1990;34:1862–1863
  19. George RC, Ball LC, Norbury PB. Susceptibility to ciprofloxacin of nosocomial gram-negative bacteria and staphylococci isolated in the UK. Antimicrob Chemother. 1990;26(F Suppl):145–156
  20. Ball P. Emerging resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus (clinical significance and therapeutic approaches). J Antimicrob Chemother. 1990;26(F Suppl):165–179
  21. Liesegang TJ, Forster RK. Spectrum of microbial keratitis in South Florida. Am J Ophthalmol. 1980;90:38–47
  22. Alfonso E, Mandelbaum S, Fox MJ, Forster RK. Ulcerative keratitis associated with contact lens wear. Am J Ophthalmol. 1986;101:429–433
  23. Kowalski RP, Pandya AN, Karenchak LM, et al.  An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeroginosa. Ophthalmology. 2001;108:1826–1829
  24. Isaacs RD, Kunke PJ, Cohen RL, et al.  Ciprofloxacin resistance in epidemic methicillin-resistant Staphylococcus aureus. Lancet. 1988;2:843
  25. Raviglione MC, Boyle JF, Mariuz P, et al.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990;34:2050–2054
  26. Marangon FB, Miller D, Alfonso EC. Impact of prior therapy on the recovery and frequency of ocular pathogens. Cornea, In press.
  27. Wilson P. Linezolid (a new antibiotic for gram-positive infections). Hosp Med. 2001;62:682–686
  28. French G. Linezolid. Int J Clin Pract. 2001;55:59–63
  29. Tsiodras S, Gold HS, Sakoulas G, et al.  Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207–208
  30. Lawyer MC, Lawyer EZ. Linezolid and reversible myelosuppression. JAMA. 2001;286:1974
  31. Dajes JJ, Hume EBH, Moreau JM, et al.  Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci. 2000;41:1432–1437
  32. Mather R, Karenchak LM, Romanowski EG, et al.  Fourth generation fluoroquinolones (new weapons in the arsenal of ophthalmic antibiotics). Am J Ophthalmol. 2002;133:463–466
  33. Malathum K, Singh KV, Murray BE. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria. Diagn Microbiol Infect Dis. 1999;35:127–133
  34. Blondeau JM, Laskowski R, Bjarnason J, et al.  Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents. 2000;14:45–50
  35. Abb J. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus (comparative evaluation by the E test and a broth microdilution method). Diagn Microbiol Infect Dis. 2002;43:319–321

☆ Supported in part by research to prevent blindness, New York, New York.Biosketches and/or additional material at www.ajo.com

PII: S0002-9394(03)01287-X

doi: 10.1016/j.ajo.2003.10.026

American Journal of Ophthalmology
Volume 137, Issue 3 , Pages 453-458 , March 2004

Article Tools

* Image Usage & Resolution